In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Motif Bio plc (MTFB), with a price target of $5. The company’s shares opened today at $1.78, close to its 52-week low of $1.54.
Byrnes said:
“We expect a clear view of the size and scope of a liver safety study after its receipt of minutes from the May 3rd Type A meeting. We anticipate an update in June. Motif also continues to expand targeted indications with recently announced agreements involving toxoplasmosis and CF-related lung infections indications.”
According to TipRanks.com, Byrnes is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -6.7% and a 29.8% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Adamas Pharmaceuticals, and Flexion Therapeutics.
Motif Bio plc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.45 and a one-year low of $1.54. Currently, Motif Bio plc has an average volume of 656.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.
